Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
作者： Jakub Adamski , Brian Godman , Gabriella Ofierska-Sujkowska , Bogusława Osińska , Harald Herholz
关键词:
摘要: … Aliterature review was undertaken to identify existing … schemes for pharmaceuticals in terms of their overall costs and benefits [… paying for cost-ineffective technologies (type I error) [36]. …
biomedcentral.com
doaj.org
springer.com
elsevier.com参考文章(59)
Scott Pegler, Jonathan Underhill, Evaluating promotional material from industry: an evidence-based approach The Pharmaceutical Journal. ,vol. 274, pp. 271- 274 ,(2005)
Thomas Rice, Pauline Rosenau, Lynn Y Unruh, Andrew J Barnes, Richard B Saltman, Ewout van Ginneken, Health systems in transition. European Observatory on Healt h Systems and Policies. ,(2010)
Catherine Sermet, Veronique Andrieu, Brian Godman, Eric Van Ganse, Alan Haycox, Jean-Pierre Reynier, Ongoing pharmaceutical reforms in France Applied Health Economics and Health Policy. ,vol. 8, pp. 7- 24 ,(2010) , 10.1007/BF03256162
Amanda Brower, 'Generic' biotech products: are the floodgates open? At whose expense? Biotechnology healthcare. ,vol. 3, pp. 22- 23 ,(2006)
Gérard de Pouvourville, Risk-sharing agreements for innovative drugs: a new solution to old problems? European Journal of Health Economics. ,vol. 7, pp. 155- 157 ,(2006) , 10.1007/S10198-006-0386-6
J. A. Cramer, Á. Benedict, N. Muszbek, A. Keskinaslan, Z. M. Khan, The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review International Journal of Clinical Practice. ,vol. 62, pp. 76- 87 ,(2007) , 10.1111/J.1742-1241.2007.01630.X
Nathalie Grandfils, Drug price setting and regulation in France Research Papers in Economics. ,(2008)
Sabina De Geest, Eduardo Sabaté, Adherence to Long-Term Therapies: Evidence for Action: European Journal of Cardiovascular Nursing. ,vol. 2, pp. 323- 323 ,(2003) , 10.1016/S1474-5151(03)00091-4
Fiona M. Clement, Anthony Harris, Jing Jing Li, Karen Yong, Karen M. Lee, Braden J. Manns, Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions JAMA. ,vol. 302, pp. 1437- 1443 ,(2009) , 10.1001/JAMA.2009.1409
Andrew Briggs, Karen Ritchie, Elisabeth Fenwick, Kalipso Chalkidou, Peter Littlejohns, Access with evidence development in the UK: past experience, current initiatives and future potential. PharmacoEconomics. ,vol. 28, pp. 163- 170 ,(2010) , 10.2165/11531410-000000000-00000